Acquired as part of its $27.8 billion takeover of Horizon Therapeutics in 2023, CD19-targeting Uplizna (inebilizumab) is the ...

European Valuations and Interpath Advisory Limited, acting on behalf of the liquidators of Surepharm Services Limited, is ...

The 4th Liquid Biopsy for Precision Oncology East Coast Summit returns to Boston with a refreshed agenda, sharpened focus, ...

TIGIT, in particular, has proved to be a tricky target for drug developers, and BeiGene's decision comes just a few months ...

Vanrafia (atrasentan) is the first drug in the selective endothelin A receptor antagonist (ERA) class to be cleared in the US ...

Pharmaceuticals are exempt from the cascade of 'Liberation Day' tariffs revealed by President Donald Trump – for now – but ...

The EMA has called a temporary halt to a phase 2 trial of Sarepta's Roche-partnered Duchenne muscular dystrophy (DMD) gene ...

The agreement with the GKV-Spitzenverband – the national association of statutory health insurance funds – means that Hemgenix (etranacogene dezaparvovec) can now be reimbursed across Germany's health ...

The Labour manifesto pledged to “maximise our potential to lead the world in clinical trials”. With our regulatory advantage ...

Under Kennedy's plan, the FDA is set to bear the brunt of the job losses, with 3,500 workers due to be shed, while the CDC is ...

Lilly said it is planning to request a re-examination of the CHMP's appraisal of Kisunla, pointing out that the drug has ...

Takeda's Adcetris has become the first drug recommended for routine NHS use as a treatment for previously untreated ...